{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:39:22Z","timestamp":1791725962717,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100006013","name":"United Arab Emirates University","doi-asserted-by":"publisher","award":["Fund no.: 12M106 [G00003664]"],"award-info":[{"award-number":["Fund no.: 12M106 [G00003664]"]}],"id":[{"id":"10.13039\/501100006013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-31001-5","type":"journal-article","created":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T17:35:36Z","timestamp":1765733736000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic potential of targeting ceramide for early cardiometabolic lipotoxicity in vivo study"],"prefix":"10.1038","volume":"16","author":[{"given":"Youssef M.","family":"Shalaby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashar","family":"Al-Zohily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjusha","family":"Sudhadev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abderrahim","family":"Nemmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhail","family":"Al-Salam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Akawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,14]]},"reference":[{"key":"31001_CR1","doi-asserted-by":"publisher","first-page":"816301","DOI":"10.3389\/fcell.2021.816301","volume":"9","author":"YM Shalaby","year":"2022","unstructured":"Shalaby, Y. M., Aidaros, A., Valappil, A., Ali, A., Akawi, N. & B. R. & Role of ceramides in the molecular pathogenesis and potential therapeutic strategies of cardiometabolic diseases: what we know so Far. Front. cell. Dev. Biology. 9, 816301 (2022).","journal-title":"Front. cell. Dev. Biology"},{"key":"31001_CR2","doi-asserted-by":"publisher","first-page":"569250","DOI":"10.3389\/fendo.2020.569250","volume":"11","author":"BC Field","year":"2020","unstructured":"Field, B. C., Gordillo, R. & Scherer, P. E. The role of ceramides in diabetes and cardiovascular disease regulation of ceramides by adipokines. Front. Endocrinol. 11, 569250 (2020).","journal-title":"Front. Endocrinol."},{"key":"31001_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.17816\/CP101","volume":"2","author":"AI Tkachev","year":"2021","unstructured":"Tkachev, A. I. et al. Ceramides: shared lipid biomarkers of cardiovascular disease and schizophrenia. Consortium Psychiatricum. 2, 33\u201341 (2021).","journal-title":"Consortium Psychiatricum"},{"key":"31001_CR4","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41569-021-00536-1","volume":"18","author":"RH Choi","year":"2021","unstructured":"Choi, R. H., Tatum, S. M., Symons, J. D., Summers, S. A. & Holland, W. L. Ceramides and other sphingolipids as drivers of cardiovascular disease. Nat. Rev. Cardiol. 18, 701\u2013711 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"31001_CR5","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1161\/hh0801.089604","volume":"88","author":"DX Zhang","year":"2001","unstructured":"Zhang, D. X., Zou, A. P. & Li, P. L. Ceramide reduces endothelium-dependent vasodilation by increasing superoxide production in small bovine coronary arteries. Circulat. Res. 88, 824\u2013831 (2001).","journal-title":"Circulat. Res."},{"key":"31001_CR6","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jacl.2020.01.005","volume":"14","author":"A Mantovani","year":"2020","unstructured":"Mantovani, A. & Dugo, C. Ceramides and risk of major adverse cardiovascular events: A meta-analysis of longitudinal studies. J. Clin. Lipidol. 14, 176\u2013185 (2020).","journal-title":"J. Clin. Lipidol."},{"key":"31001_CR7","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1161\/ATVBAHA.120.315530","volume":"41","author":"VC Vasile","year":"2021","unstructured":"Vasile, V. C. et al. Ceramide scores predict cardiovascular risk in the community. Arterioscler. Thromb. Vasc. Biol. 41, 1558\u20131569 (2021).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"31001_CR8","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1161\/ATVBAHA.118.311199","volume":"38","author":"JW Meeusen","year":"2018","unstructured":"Meeusen, J. W. et al. Plasma ceramides: a novel predictor of major adverse cardiovascular events after coronary angiography. Arterioscler. Thromb. Vasc. Biol. 38, 1933\u20131939 (2018).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"31001_CR9","doi-asserted-by":"publisher","first-page":"570628","DOI":"10.3389\/fendo.2020.570628","volume":"11","author":"M Hilvo","year":"2020","unstructured":"Hilvo, M., Vasile, V. C., Donato, L. J., Hurme, R. & Laaksonen, R. Ceramides and ceramide scores: clinical applications for cardiometabolic risk stratification. Front. Endocrinol. 11, 570628 (2020).","journal-title":"Front. Endocrinol."},{"key":"31001_CR10","doi-asserted-by":"publisher","first-page":"e022852","DOI":"10.1161\/JAHA.121.022852","volume":"11","author":"N Akhiyat","year":"2022","unstructured":"Akhiyat, N. et al. Plasma ceramide levels are elevated in patients with early coronary atherosclerosis and endothelial dysfunction. J. Am. Heart Association. 11, e022852 (2022).","journal-title":"J. Am. Heart Association"},{"key":"31001_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12933-023-01747-1","volume":"22","author":"R Liu","year":"2023","unstructured":"Liu, R. et al. Acid Sphingomyelinase promotes diabetic cardiomyopathy via NADPH oxidase 4 mediated apoptosis. Cardiovasc. Diabetol. 22, 25 (2023).","journal-title":"Cardiovasc. Diabetol."},{"key":"31001_CR12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/cells11020206","volume":"11","author":"AU B\u0142achnio-Zabielska","year":"2022","unstructured":"B\u0142achnio-Zabielska, A. U. et al. Cers1 but not CerS5 gene silencing, improves insulin sensitivity and glucose uptake in skeletal muscle. Cells 11, 206 (2022).","journal-title":"Cells"},{"key":"31001_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.cmet.2007.01.002","volume":"5","author":"WL Holland","year":"2007","unstructured":"Holland, W. L. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metabol. 5, 167\u2013179 (2007).","journal-title":"Cell Metabol."},{"key":"31001_CR14","doi-asserted-by":"publisher","first-page":"e007931","DOI":"10.1161\/JAHA.117.007931","volume":"7","author":"LR Peterson","year":"2018","unstructured":"Peterson, L. R. et al. Ceramide remodeling and risk of cardiovascular events and mortality. J. Am. Heart Association. 7, e007931 (2018).","journal-title":"J. Am. Heart Association"},{"key":"31001_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00395-014-0445-6","volume":"109","author":"JN Simon","year":"2014","unstructured":"Simon, J. N. et al. Ceramide-mediated depression in cardiomyocyte contractility through PKC activation and modulation of myofilament protein phosphorylation. Basic Res. Cardiol. 109, 1\u201315 (2014).","journal-title":"Basic Res. Cardiol."},{"key":"31001_CR16","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41574-020-0320-5","volume":"16","author":"SM Turpin-Nolan","year":"2020","unstructured":"Turpin-Nolan, S. M. & Br\u00fcning, J. C. The role of ceramides in metabolic disorders: when size and localization matters. Nat. Reviews Endocrinol. 16, 224\u2013233 (2020).","journal-title":"Nat. Reviews Endocrinol."},{"key":"31001_CR17","doi-asserted-by":"publisher","first-page":"9697","DOI":"10.3390\/ijms23179697","volume":"23","author":"QWC Ho","year":"2022","unstructured":"Ho, Q. W. C., Zheng, X. & Ali, Y. Ceramide acyl chain length and its relevance to intracellular lipid regulation. Int. J. Mol. Sci. 23, 9697 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"31001_CR18","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","volume":"398","author":"E Brown","year":"2021","unstructured":"Brown, E., Heerspink, H. J., Cuthbertson, D. J. & Wilding, J. P. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. J. Lancet. 398, 262\u2013276 (2021).","journal-title":"J. Lancet"},{"key":"31001_CR19","doi-asserted-by":"publisher","unstructured":"Li, S. et al. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. bmj https:\/\/doi.org\/10.1136\/bmj.n1091 (2021).","DOI":"10.1136\/bmj.n1091"},{"key":"31001_CR20","doi-asserted-by":"publisher","first-page":"2496795","DOI":"10.1080\/07853890.2025.2496795","volume":"57","author":"YM Shalaby","year":"2025","unstructured":"Shalaby, Y. M. et al. Impact of sodium-glucose cotransporter-2 inhibitors on aging biomarkers and plasma ceramide levels in type 2 diabetes: beyond glycemic control. Ann. Med. 57, 2496795 (2025).","journal-title":"Ann. Med."},{"key":"31001_CR21","doi-asserted-by":"publisher","first-page":"862394","DOI":"10.3389\/fendo.2022.862394","volume":"13","author":"M El-Shafey","year":"2022","unstructured":"El-Shafey, M. et al. Role of dapagliflozin and liraglutide on diabetes-induced cardiomyopathy in rats: implication of oxidative stress, inflammation, and apoptosis. Front. Endocrinol. 13, 862394 (2022).","journal-title":"Front. Endocrinol."},{"key":"31001_CR22","doi-asserted-by":"publisher","first-page":"10624","DOI":"10.1038\/s41598-021-90191-w","volume":"11","author":"S Sivalingam","year":"2021","unstructured":"Sivalingam, S. et al. The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes. Sci. Rep. 11, 10624 (2021).","journal-title":"Sci. Rep."},{"key":"31001_CR23","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s43440-021-00224-4","volume":"73","author":"J Cessario","year":"2021","unstructured":"Cessario, J., Pierre-Louis, V., Wahl, J. & Li, Z. Empagliflozin, alone or in combination with liraglutide, limits cell death in vitro: role of oxidative stress and nitric oxide. Pharmacol. Rep. 73, 858\u2013867 (2021).","journal-title":"Pharmacol. Rep."},{"key":"31001_CR24","doi-asserted-by":"publisher","first-page":"670389","DOI":"10.3389\/fphar.2021.670389","volume":"12","author":"Q Cao","year":"2021","unstructured":"Cao, Q. et al. Sitagliptin reduces endothelial dysfunction and apoptosis induced by high-fat diet and palmitate in thoracic aortas and endothelial cells via ROS-ER stress-CHOP pathway. Front. Pharmacol. 12, 670389 (2021).","journal-title":"Front. Pharmacol."},{"key":"31001_CR25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.bbrc.2022.09.018","volume":"629","author":"H Cai","year":"2022","unstructured":"Cai, H., Zhou, L., Liu, J., Li, Z. & Chen, S. Independent and combined effects of liraglutide and aerobic interval training on glycemic control and cardiac protection in diabetic cardiomyopathy rats. Biochem. Biophys. Res. Commun. 629, 112\u2013120 (2022).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"31001_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.regpep.2010.08.007","volume":"166","author":"J Vaghasiya","year":"2011","unstructured":"Vaghasiya, J., Sheth, N., Bhalodia, Y. & Manek, R. Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes. Regul. Pept. 166, 48\u201354 (2011).","journal-title":"Regul. Pept."},{"key":"31001_CR27","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.neuropharm.2014.10.007","volume":"89","author":"NN Nassar","year":"2015","unstructured":"Nassar, N. N., Al-Shorbagy, M. Y., Arab, H. H. & Abdallah, D. M. Saxagliptin: a novel antiparkinsonian approach. Neuropharmacology 89, 308\u2013317 (2015).","journal-title":"Neuropharmacology"},{"key":"31001_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12944-024-02080-6","volume":"23","author":"YM Shalaby","year":"2024","unstructured":"Shalaby, Y. M. et al. Circulating ceramide levels and ratios in Emirati youth under 18 years: associations with cardiometabolic risk factors. Lipids Health Dis. 23, 93 (2024).","journal-title":"Lipids Health Dis."},{"key":"31001_CR29","doi-asserted-by":"publisher","first-page":"1185595","DOI":"10.3389\/fcvm.2023.1185595","volume":"10","author":"L Ren","year":"2023","unstructured":"Ren, L. et al. Abnormal plasma ceramides refine high-risk patients with worsening heart failure. Front. Cardiovasc. Med. 10, 1185595 (2023).","journal-title":"Front. Cardiovasc. Med."},{"key":"31001_CR30","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1210\/er.2014-1035","volume":"35","author":"EE Mulvihill","year":"2014","unstructured":"Mulvihill, E. E. & Drucker, D. J. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr. Rev. 35, 992\u20131019 (2014).","journal-title":"Endocr. Rev."},{"key":"31001_CR31","doi-asserted-by":"publisher","first-page":"8309723","DOI":"10.1155\/2018\/8309723","volume":"2018","author":"W Zheng","year":"2018","unstructured":"Zheng, W. et al. Dipeptidyl-peptidase 4 inhibitor sitagliptin ameliorates hepatic insulin resistance by modulating inflammation and autophagy in ob\/ob mice. Int. J. Endocrinol. 2018, 8309723 (2018).","journal-title":"Int. J. Endocrinol."},{"key":"31001_CR32","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.2337\/db14-0804","volume":"64","author":"AR Aroor","year":"2015","unstructured":"Aroor, A. R. et al. Dipeptidyl peptidase-4 Inhibition ameliorates Western diet\u2013induced hepatic steatosis and insulin resistance through hepatic lipid remodeling and modulation of hepatic mitochondrial function. Diabetes 64, 1988\u20132001 (2015).","journal-title":"Diabetes"},{"key":"31001_CR33","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41420-021-00625-7","volume":"7","author":"X Wang","year":"2021","unstructured":"Wang, X. et al. Dipeptidyl peptidase-4 (DPP4) inhibitor sitagliptin alleviates liver inflammation of diabetic mice by acting as a ROS scavenger and inhibiting the NF\u03baB pathway. Cell. Death Discovery. 7, 236 (2021).","journal-title":"Cell. Death Discovery"},{"key":"31001_CR34","first-page":"619","volume":"29","author":"PP Sordillo","year":"2015","unstructured":"Sordillo, P. P., Sordillo, D. C. & Helson, L. The prolonged QT Interval: role of pro-inflammatory cytokines, reactive oxygen species and the ceramide and sphingosine-1 phosphate pathways. in vivo 29, 619\u2013636 (2015).","journal-title":"in vivo"},{"key":"31001_CR35","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1016\/j.jacc.2021.03.314","volume":"77","author":"N Akawi","year":"2021","unstructured":"Akawi, N. et al. Fat-secreted ceramides regulate vascular redox state and influence outcomes in patients with cardiovascular disease. J. Am. Coll. Cardiol. 77, 2494\u20132513 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"31001_CR36","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3389\/fphys.2019.00268","volume":"10","author":"VS Rocha","year":"2019","unstructured":"Rocha, V. S. et al. High-fat diet-induced obesity model does not promote endothelial dysfunction via increasing Leptin\/Akt\/eNOS signaling. Front. Physiol. 10, 268 (2019).","journal-title":"Front. Physiol."},{"key":"31001_CR37","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev-physiol-031620-093815","volume":"83","author":"B Chaurasia","year":"2021","unstructured":"Chaurasia, B. & Summers, S. A. Ceramides in metabolism: key lipotoxic players. Annu. Rev. Physiol. 83, 303\u2013330 (2021).","journal-title":"Annu. Rev. Physiol."},{"key":"31001_CR38","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3390\/jcm10040792","volume":"10","author":"E Hajduch","year":"2021","unstructured":"Hajduch, E., Lachkar, F., Ferr\u00e9, P. & Foufelle, F. Roles of ceramides in non-alcoholic fatty liver disease. J. Clin. Med. 10, 792 (2021).","journal-title":"J. Clin. Med."},{"key":"31001_CR39","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3389\/fendo.2019.00665","volume":"10","author":"M Jiang","year":"2019","unstructured":"Jiang, M., Li, C., Liu, Q., Wang, A. & Lei, M. Inhibiting ceramide synthesis attenuates hepatic steatosis and fibrosis in rats with non-alcoholic fatty liver disease. Front. Endocrinol. 10, 665 (2019).","journal-title":"Front. Endocrinol."},{"key":"31001_CR40","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1194\/jlr.M081398","volume":"59","author":"F Norheim","year":"2018","unstructured":"Norheim, F. et al. Genetic, dietary, and sex-specific regulation of hepatic ceramides and the relationship between hepatic ceramides and IR [S]. J. Lipid Res. 59, 1164\u20131174 (2018).","journal-title":"J. Lipid Res."},{"key":"31001_CR41","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13287-025-04340-3","volume":"16","author":"P Haxhikadrija","year":"2025","unstructured":"Haxhikadrija, P. et al. Inhibition of ceramide synthesis improves the outcome of ischemia\/reperfusion injury in cardiomyocytes derived from human induced pluripotent stem cell. Stem Cell Res. Ther. 16, 190 (2025).","journal-title":"Stem Cell Res. Ther."},{"key":"31001_CR42","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2147\/DMSO.S132537","volume":"10","author":"E Civantos","year":"2017","unstructured":"Civantos, E. et al. Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a\/Keap-1\/Nrf2 antioxidant pathway. Diabetes metabolic syndrome obesity: targets therapy 10, 207\u2013222 (2017).","journal-title":"Diabetes metabolic syndrome obesity: targets therapy"},{"key":"31001_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13098-015-0095-3","volume":"7","author":"MA Alam","year":"2015","unstructured":"Alam, M. A., Chowdhury, M. R. H., Jain, P., Sagor, M. A. T. & Reza, H. M. DPP-4 inhibitor sitagliptin prevents inflammation and oxidative stress of heart and kidney in two kidney and one clip (2K1C) rats. Diabetol. Metab. Syndr. 7, 1\u201310 (2015).","journal-title":"Diabetol. Metab. Syndr."},{"key":"31001_CR44","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1007\/s00125-009-1482-9","volume":"52","author":"V De Mello","year":"2009","unstructured":"De Mello, V. et al. Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease. Diabetologia 52, 2612\u20132615 (2009).","journal-title":"Diabetologia"},{"key":"31001_CR45","doi-asserted-by":"publisher","first-page":"5457","DOI":"10.2147\/JIR.S380285","volume":"15","author":"SY Chen","year":"2022","unstructured":"Chen, S. Y. et al. DPP4 as a potential candidate in cardiovascular disease. Journal Inflamm. research 15, 5457\u20135469 (2022).","journal-title":"Journal Inflamm. research"},{"key":"31001_CR46","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1743-7075-9-71","volume":"9","author":"MM Hussain","year":"2012","unstructured":"Hussain, M. M., Jin, W. & Jiang, X. C. Mechanisms involved in cellular ceramide homeostasis. Nutr. Metabolism. 9, 71 (2012).","journal-title":"Nutr. Metabolism"},{"key":"31001_CR47","doi-asserted-by":"publisher","first-page":"1343181","DOI":"10.3389\/fneph.2024.1343181","volume":"4","author":"Y Morita","year":"2024","unstructured":"Morita, Y. et al. Alterations in urinary ceramides, sphingoid bases, and their phosphates among patients with kidney disease. Front. Nephrol. 4, 1343181 (2024).","journal-title":"Front. Nephrol."},{"key":"31001_CR48","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.2337\/dc14-0865","volume":"37","author":"A Avogaro","year":"2014","unstructured":"Avogaro, A. & Fadini, G. P. The effects of dipeptidyl peptidase-4 Inhibition on microvascular diabetes complications. Diabetes Care. 37, 2884\u20132894 (2014).","journal-title":"Diabetes Care"},{"key":"31001_CR49","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12933-025-02607-w","volume":"24","author":"D Hullon","year":"2025","unstructured":"Hullon, D. et al. The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF). Cardiovasc. Diabetol. 24, 70 (2025).","journal-title":"Cardiovasc. Diabetol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31001-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31001-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31001-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T23:02:41Z","timestamp":1768345361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31001-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,14]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["31001"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-31001-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,14]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1599"}}